INDV
IndiviorDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Bull case: successful continuation of US commercial momentum and improved payer coverage drive >25% upside within 6–12 months as revenue/margin mix improves and valuation multiple re-rates.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Bear case: regulatory or litigation setbacks, or rapid generic entry, drive material downside (>25%) as revenue shocks and multiple compression occur.
Momentum
47
Value
54
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $33.36 · Bull $45.66 · Bear $26.34
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $50.83
Why
Momentum47 · Δ7d -27.8
Value54 · Δ7d +0.1
Sentiment33 · Δ7d +0.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
47
26% active weight
Current posture
7d trendSoftening
Δ7d
-27.8
Δ21d
-21.9
Value
54
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.1
Sentiment
33
34% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+1.1
Why this grade
Composite grade D. Momentum 47.2 / Value 53.9 / Sentiment 33.1
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$4.93B
Beta
1.14
Shares Out
124.85M
P/E (TTM)
37.8
P/S (TTM)
3.84
P/FCF (TTM)
37.72
Rev YoY
+19.2%
EPS YoY
+83.5%
Gross Margin
+83.1%
Op Margin
+18.7%
Net Debt
$156M
Current Ratio
0.86
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology